Liver Cancer
SCOPUS (2012-2023)SCIE-ISI
2235-1795
1664-5553
Thụy Sĩ
Cơ quản chủ quản: S. Karger AG , KARGER
Lĩnh vực:
OncologyHepatology
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)<b><i>Background:</i></b> Hepatocellular carcinoma (HCC) (about 85–90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese peopl... ...
Tập 7 Số 3 - Trang 235-260 - 2018
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh ClassificationsAim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods:... ...
Tập 6 Số 3 - Trang 204-215 - 2017
Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma<b><i>Background and Aims:</i></b> Combining anti-angiogenic therapy with immune checkpoint blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for hepatocellular carcinoma (HCC). Tyrosine kinase inhibitors are well-known anti-angiogenic agents and offer potential for combination with anti-PD-1 antibodies. This study investigated th... ...
Tập 9 Số 3 - Trang 338-357 - 2020
A Worldwide Survey of the Current Daily Practice in Liver Surgery<b><i>Background:</i></b> Liver resection remains the mainstay of curative treatment for liver malignancies. A variety of preoperative assessments and surgical techniques have improved the short- and long-term outcomes of liver resection in patients with liver tumors. Recently, laparoscopic hepatectomies have been increasingly performed. The aim of the present study... ...
Tập 2 Số 1 - Trang 55-66 - 2013
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
Tập 8 Số 6 - Trang 413-426 - 2019
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis<b><i>Objective:</i></b> The aim of this study was to evaluate the performance of pretreatment computed tomography (CT) enhancement of hepatocellular carcinoma (HCC) as a potential predictor of response to lenvatinib and its relevance to survival outcomes. <b><i>Methods:</i></b> We evaluated 51 consecutive patients who received lenvatinib tre... ...
Tập 9 Số 3 - Trang 275-292 - 2020
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma<b><i>Background:</i></b> There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore candidates for second-line agents in the patients with failed lenvatinib therapy. <b><i>Methods:&l... ...
Tập 10 Số 5 - Trang 473-484 - 2021
Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up<b><i>Background:</i></b><b> </b>The outcomes of hepatic resection in intrahepatic cholangiocarcinoma (ICC) patients with diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL) (metabolic components) remain unclear. <b><i>Methods:</i></b><b> </b>The outcomes of 43 ICC patients without known risk factors for I... ...
Tập 5 Số 2 - Trang 107-120 - 2016